Left atrium in heart failure with preserved ejection fraction structure, function, and significance

Circulation: Heart Failure

Volumn 7, Issue 6, 2014, Pages 1042-1049

  Rossi, Andrea ^a   Gheorghiade, Mihai ^b   Triposkiadis, Filippos ^c   Solomon, Scott D ^d   Pieske, Burkert ^e   Butler, Javed ^f  

^a UNIVERSITY OF VERONA   (Italy)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF THESSALY   (Greece)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Heart failure

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ENDOCRINE FUNCTION; FUNCTIONAL ANATOMY; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LUNG PRESSURE; MECHANORECEPTOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; FEMALE; HEART ATRIUM FUNCTION; HEART CONTRACTION; HEART FAILURE; HEMODYNAMICS; MALE; MUSCLE CELL; PATHOLOGY; PHYSIOLOGY;

ATRIAL FUNCTION, LEFT; ATRIAL REMODELING; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MUSCLE CELLS; MYOCARDIAL CONTRACTION; PROGNOSIS;

EID: 84925744564     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001276     Document Type: Article

References (72)

1. Corradi D, Maestri R, Macchi E, Callegari S. The atria: from morphology to function. J Cardiovasc Electrophysiol. 2011;22:223-235.
2. Barbier P, Solomon SB, Schiller NB, Glantz SA. Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function. Circulation. 1999;100:427-436.
3. Karayannis G, Kitsios G, Kotidis H, Triposkiadis F. Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure. Heart Fail Rev. 2008;13:91-98.
4. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
5. Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res. 2005;68:8-17.
6. Scheuer DA, Thrasher TN, Ramsay DJ. Role of renal sympathetic nerves in renin inhibition by elevated left atrial pressure. Am J Physiol. 1989;256(2 Pt 2):R413-R420.
7. Coote JH. A role for the paraventricular nucleus of the hypothalamus in the autonomic control of heart and kidney. Exp Physiol. 2005;90:169-173.
8. LeJemtel TH, Serrano C. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. Int J Cardiol. 2007;120:1-9.
9. Tops LF, van der Wall EE, Schalij MJ, Bax JJ. Multi-modality imaging to assess left atrial size, anatomy and function. Heart. 2007;93:1461-1470.
10. Messika-Zeitoun D, Bellamy M, Avierinos JF, Breen J, Eusemann C, Rossi A, Behrenbeck T, Scott C, Tajik JA, Enriquez-Sarano M. Left atrial remodelling in mitral regurgitation-methodologic approach, physiological determinants, and outcome implications: a prospective quantitative Doppler-echocardiographic and electron beam-computed tomographic study. Eur Heart J. 2007;28:1773-1781.
11. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
12. Stojanovska J, Cronin P, Patel S, Gross BH, Oral H, Chughtai K, Kazerooni EA. Reference normal absolute and indexed values from ECG-gated MDCT: left atrial volume, function, and diameter. AJR Am J Roentgenol. 2011;197:631-637.
13. Maceira AM, Cosín-Sales J, Roughton M, Prasad SK, Pennell DJ. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:65.
14. Stefanadis C, Dernellis J, Stratos C, Tsiamis E, Tsioufis C, Toutouzas K, Vlachopoulos C, Pitsavos C, Toutouzas P. Assessment of left atrial pressure-area relation in humans by means of retrograde left atrial catheterization and echocardiographic automatic boundary detection: effects of dobutamine. J Am Coll Cardiol. 1998;31:426-436.
15. Triposkiadis F, Harbas C, Sitafidis G, Skoularigis J, Demopoulos V, Kelepeshis G. Echocardiographic assessment of left atrial ejection force and kinetic energy in chronic heart failure. Int J Cardiovasc Imaging. 2008;24:15-22.
16. Nagueh SF, Sun H, Kopelen HA, Middleton KJ, Khoury DS. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol. 2001;37:278-285.
17. Cameli M, Lisi M, Righini FM, Massoni A, Natali BM, Focardi M, Tacchini D, Geyer A, Curci V, Di Tommaso C, Lisi G, Maccherini M, Chiavarelli M, Massetti M, Tanganelli P, Mondillo S. Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 2013;111:595-601.
18. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103:670-677.
19. Boixel C, Fontaine V, Rücker-Martin C, Milliez P, Louedec L, Michel JB, Jacob MP, Hatem SN. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 2003;42:336-344.
20. Dolgilevich SM, Siri FM, Atlas SA, Eng C. Changes in collagenase and collagen gene expression after induction of aortocaval fistula in rats. Am J Physiol Heart Circ Physiol. 2001;281:H207-H214.
21. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-147.
22. Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res. 2004;63:236-244.
23. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.
24. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2014;63:407-416.
25. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124:2491-2501.
26. Rossi A, Cicoira M, Florea VG, Golia G, Florea ND, Khan AA, Murray ST, Nguyen JT, O'Callaghan P, Anand IS, Coats A, Zardini P, Vassanelli C, Henein M. Chronic heart failure with preserved left ventricular ejection fraction: diagnostic and prognostic value of left atrial size. Int J Cardiol. 2006;110:386-392.
27. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119-1126.
28. Prioli A, Marino P, Lanzoni L, Zardini P. Increasing degrees of left ventricular filling impairment modulate left atrial function in humans. Am J Cardiol. 1998;82:756-761.
29. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207.
30. Tan YT, Wenzelburger F, Lee E, Nightingale P, Heatlie G, Leyva F, Sanderson JE. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart. 2010;96:1017-1023.
31. Triposkiadis F, Moyssakis I, Hadjinikolaou L, Makris T, Zioris H, Hatzizaharias A, Kyriakidis M. Left atrial systolic function is depressed in idiopathic and preserved in ischemic dilated cardiomyopathy. Eur J Clin Invest. 1999;29:905-912.
32. Kusunose K, Motoki H, Popovic ZB, Thomas JD, Klein AL, Marwick TH. Independent association of left atrial function with exercise capacity in patients with preserved ejection fraction. Heart. 2012;98:1311-1317.
33. Kurt M, Wang J, Torre-Amione G, Nagueh SF. Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging. 2009;2:10-15.
34. Santos AB, Kraigher-Krainer E, Gupta DK, Claggett B, Zile MR, Pieske B, Voors AA, Lefkowitz M, Bransford T, Shi V, Parker M, McMurray JJ, Shah AM, Solomon SD for the PARAMOUNT Investigators. Impaired left atrial function in heart failure with preserved ejection fraction [published online ahead of print Aug 19, 2014]. Eur J Heart Fail. doi: 10.1002/ ejhf.147. http://onlinelibrary.wiley.com/doi/10.1002/ejhf.147/full.
35. Laurent G, Eicher JC, Mathe A, Bertaux G, Barthez O, Debin R, Billard C, Philip JL, Wolf JE. Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: a pilot study prior to a national clinical research programme. Eur J Heart Fail. 2013;15:85-93.
36. Kaneko H, Koike A, Senoo K, Tanaka S, Suzuki S, Nagayama O, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Yajima J, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T. Role of cardiopulmonary dysfunction and left atrial remodeling in development of acute decompensated heart failure in chronic heart failure with preserved left ventricular ejection fraction. J Cardiol. 2012;59:359-365.
37. Braunwald E, Awe WC. The syndrome of severe mitral regurgitation with normal left atrial pressure. Circulation. 1963;27:29-35.
38. Le Tourneau T, Richardson M, Juthier F, Modine T, Fayad G, Polge AS, Ennezat PV, Bauters C, Vincentelli A, Deklunder G. Echocardiography predictors and prognostic value of pulmonary artery systolic pressure in chronic organic mitral regurgitation. Heart. 2010;96:1311-1317.
39. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128:1085-1093.
40. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
41. Ausma J, Wijffels M, Thoné F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157-3163.
42. Rossi A, Enriquez-Sarano M, Burnett JC, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000;35:1256-1262.
43. Gupta DK, Shah AM, Giugliano RP, Ruff CT, Antman EM, Grip LT, Deenadayalu N, Hoffman E, Patel I, Shi M, Mercuri M, Mitrovic V, Braunwald E, Solomon SD; Effective aNticoaGulation with factor xA next GEneration in AF-Thrombolysis In Myocardial Infarction 48 Echocardiographic Study Investigators. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J. 2014;35:1457-1465.
44. Rossi A, Cicoira M, Zanolla L, Sandrini R, Golia G, Zardini P, Enriquez-Sarano M. Determinants and prognostic value of volume in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:1425-1431.
45. Solti F, Vecsey T, Kékesi V, Juhász-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989;23:882-886.
46. Bode F, Katchman A, Woosley RL, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation. 2000;101:2200-2205.
47. Laukkanen JA, Kurl S, Eränen J, Huttunen M, Salonen JT. Left atrium size and the risk of cardiovascular death in middle-aged men. Arch Intern Med. 2005;165:1788-1793.
48. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001;76:467-475.
49. Osranek M, Fatema K, Qaddoura F, Al-Saileek A, Barnes ME, Bailey KR, Gersh BJ, Tsang TS, Zehr KJ, Seward JB. Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol. 2006;48:779-786.
50. Takemoto Y, Barnes ME, Seward JB, Lester SJ, Appleton CA, Gersh BJ, Bailey KR, Tsang TS. Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol. 2005;96:832-836.
51. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-2550.
52. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 2014;7:104-115.
53. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-1395.
54. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781-791.
55. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277.
56. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J, McKelvie RS; Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol. 2007;49:687-694.
57. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
58. He KL, Burkhoff D, Leng WX, Liang ZR, Fan L, Wang J, Maurer MS. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. Am J Cardiol. 2009;103:845-851.
59. Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman DW, Solomon SD. Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study. JACC Heart Fail. 2013;1:156-163.
60. Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M. Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol. 2008;101:639-644.
61. Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol. 2013;112:1158-1164.
62. Yamamoto K, Origasa H, Suzuki Y, Takahashi T, Shinozaki T, Watanabe T, Sakata Y, Izumi C, Taira K, Hori M; J-DHF Investigators. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction-a report from the Japanese Diastolic Heart Failure Study (J-DHF). J Cardiol. 2014;63:424-431.
63. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284-1289.
64. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol. 2003;42:1206-1207.
65. Rossi A, Temporelli PL, Quintana M, Dini FL, Ghio S, Hillis GS, Klein A, Ajmone Marsan N, Prior D, Yu CM, Poppe KK, Doughty RN, Whalley GA, on behalf of the MeRGE Heart Failure Collaborators. Independent relationship of LA size and mortality in patients with heart failure: An Individual Patient Meta-Analysis of Longitudinal Data (MeRGE Heart Failure) Eur J Heart Fail. 2009;11:929-936.
66. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014;2:97-112.
67. Tripepi G, Benedetto FA, Mallamaci F, Tripepi R, Malatino L, Zoccali C. Left atrial volume monitoring and cardiovascular risk in patients with end-stage renal disease: a prospective cohort study. J Am Soc Nephrol. 2007;18:1316-1322.
68. Antonini-Canterin F, Beladan CC, Popescu BA, Ginghina C, Popescu AC, Piazza R, Leiballi E, Zingone B, Nicolosi GL. Left atrial remodelling early after mitral valve repair for degenerative mitral regurgitation. Heart. 2008;94:759-764.
69. Tsang TS, Barnes ME, Abhayaratna WP, Cha SS, Gersh BJ, Langins AP, Green TD, Bailey KR, Miyasaka Y, Seward JB. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol. 2006;97:916-920.
70. Gerds E, Watchell K, Omvik O, Otterstad JE, Oikarinen L, Boman K, Dahlöf B, Devereux RB. LA size and risk of major cardiovascualr events during antihypertensive treatment: losartan intervention for end-point reduction in hipertension trail. Hypertension. 2007;49:311-316.
71. Kuperstein R, Goldenberg I, Moss AJ, Solomon S, Bourgoun M, Shah A, McNitt S, Zareba W, Klempfner R. Left atrial volume and the benefit of cardiac resynchronization therapy in the MADIT-CRT trial. Circ Heart Fail. 2014;7:154-160.
72. Pieske B, Butler J, Filippatos G, Lam C, Maggioni A, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Muller K, Roessig L, Gheorghiade M. Design and Rationale of the SOluble guanylate Cyclase stimulatoR in heart failurEStudies (SOCRATES). Eur J Heart Fail. 2014;16 (Supplement 2): 95.